These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1786145)

  • 41. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.
    Wolinsky SM; Wike CM; Korber BT; Hutto C; Parks WP; Rosenblum LL; Kunstman KJ; Furtado MR; Muñoz JL
    Science; 1992 Feb; 255(5048):1134-7. PubMed ID: 1546316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
    Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
    J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.
    Keller PM; Arnold BA; Shaw AR; Tolman RL; Van Middlesworth F; Bondy S; Rusiecki VK; Koenig S; Zolla-Pazner S; Conard P
    Virology; 1993 Apr; 193(2):709-16. PubMed ID: 7681612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera.
    Gómez CE; López-Campistrous AE; Duarte CA
    J Virol Methods; 1998 Mar; 71(1):7-16. PubMed ID: 9628216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA.
    Tiwari RP; Jain A; Khan Z; Kumar P; Bhrigu V; Bisen PS
    J Immunol Methods; 2013 Jan; 387(1-2):157-66. PubMed ID: 23098841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
    Kim YB; Han DP; Cao C; Cho MW
    Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
    Nkengasong JN; Peeters M; Ndumbe P; Janssens W; Willems B; Fransen K; Ngolle M; Piot P; van der Groen G
    AIDS; 1994 Aug; 8(8):1089-96. PubMed ID: 7986404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients.
    Von Brunn A; Reichhuber C; Pfaff E; Wizemann H
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1459-65. PubMed ID: 8679289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS.
    Page M; Vella C; Corcoran T; Dilger P; Ling C; Heath A; Thorpe R
    AIDS; 1992 May; 6(5):441-6. PubMed ID: 1616648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.
    Cheingsong-Popov R; Lister S; Callow D; Kaleebu P; Beddows S; Weber J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1379-86. PubMed ID: 7888191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of linear antigenic epitopes on GP120 encoded in sibling clones of novel New York HIV-1 subtype B isolates.
    Riley JP; Pestano GA; Harewood K; Alfred LJ; Guyden J; Boto WM
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S83-91. PubMed ID: 8574151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.
    Permar SR; Fong Y; Vandergrift N; Fouda GG; Gilbert P; Parks R; Jaeger FH; Pollara J; Martelli A; Liebl BE; Lloyd K; Yates NL; Overman RG; Shen X; Whitaker K; Chen H; Pritchett J; Solomon E; Friberg E; Marshall DJ; Whitesides JF; Gurley TC; Von Holle T; Martinez DR; Cai F; Kumar A; Xia SM; Lu X; Louzao R; Wilkes S; Datta S; Sarzotti-Kelsoe M; Liao HX; Ferrari G; Alam SM; Montefiori DC; Denny TN; Moody MA; Tomaras GD; Gao F; Haynes BF
    J Clin Invest; 2015 Jul; 125(7):2702-6. PubMed ID: 26053661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.